检索结果-南通市图书馆

MyCTC chip:microfluidic-based drug screen with patient-derived tumour cells from liquid biopsies

Microsystems & Nanoengineering 2022年第6期8卷 125-135页

作者： Fabienne D.Schwab Manuel C.Scheidmann Lauren L.Ozimski AndréKling Lucas Armbrecht till ryser Ilona Krol Karin Strittmatter Bich Doan Nguyen-Sträuli Francis Jacob AndréFedier Viola Heinzelmann-Schwarz Andreas Wicki Petra S.Dittrich Nicola Aceto Department of Biomedicine Cancer Metastasis LaboratoryUniversity of BaselBaselSwitzerland Department of Gynaecologic Oncology University Hospital BaselBaselSwitzerland Department of Biology Swiss Federal Institute of Technology Zurich(ETH Zurich)ZurichSwitzerland Department of Biosystems Science and Engineering Swiss Federal Institute of Technology Zurich(ETH Zurich)BaselSwitzerland Department of Gynaecology University Hospital Zurich and University of ZurichZurichSwitzerland Department of Biomedicine Ovarian Cancer ResearchUniversity Hospital Basel and University of BaselBaselSwitzerland University of Zurich and University Hospital Zurich ZurichSwitzerland

Cancer patients with advanced disease are characterized by intrinsic challenges in predicting drug response patterns,often leading to ineffective *** clinical practice for treatment decision-making is commonly based on primary or secondary tumour biopsies,yet when disease progression accelerates,tissue biopsies are not performed on a regular *** is in this context that liquid biopsies may offer a unique window to uncover key vulnerabilities,providing valuable information about previously underappreciated treatment ***,we present MyCTC chip,a novel microfluidic device enabling the isolation,culture and drug susceptibility testing of cancer cells derived from liquid *** cell capture is achieved through a label-free,antigen-agnostic enrichment method,and it is followed by cultivation in dedicated conditions,allowing on-chip expansion of captured *** growth,cancer cells are then transferred to drug screen chambers located within the same device,where multiple compounds can be tested *** demonstrate MyCTC chip performance by means of spike-in experiments with patientderived breast circulating tumour cells,enabling>95%capture rates,as well as prospective processing of blood from breast cancer patients and ascites fluid from patients with ovarian,tubal and endometrial cancer,where sensitivity to specific chemotherapeutic agents was ***,we provide evidence that MyCTC chip may be used to identify personalized drug response patterns in patients with advanced metastatic disease and with limited treatment opportunities.

关键词： fluid transferred Together

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：